A Phase 3 interventional study of Cilostazol and Methotrexate in Rheumatoid Arthritis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-10.
Sponsored by Tanta University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arthritis, Rheumatoid by Tanta University — 11 open to participants now, 11 under way, 3 of them phase 3. Arthritis, Rheumatoid · Tanta University.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 4th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →11 of the 15 studies in Arthritis, Rheumatoid by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 4
First in 2019; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 63 across the 14 interventional studies, 30 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Arthritis, Rheumatoid by Tanta University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800351Phase 3Tanta UniversityNicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis | 2027-02 |
| NCT07401732Tanta UniversityDysphagia in Rheumatoid Arthritis | 2026-11 |
| NCT06998628Tanta UniversityPentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis | 2027-05-30 |
| NCT07901309Tanta UniversityEfficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis | 2027-06-30 |
| NCT07745426Tanta UniversityClinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims at evaluating the therapeutic effects of Cilostazol as adjuvant therapies to low dose of Methotrexate in patients with Rheumatoid Arthritis and to evaluate their impact on Cyclic adenosine monophosphate(CAMP), Heme Oxygenase-1(HO-1).
Rheumatoid arthritis (RA) is characterized by the presence of hyperplastic synovium in association with immune-mediated inflammatory synovitis associated with chronic production of proinflammatory cytokines, which lead to cartilage and bone degradation .This study is a randomized, controlled double blind placebo-controlled ,prospective study to evaluate the potential therapeutic effects of Cilostazol on synovial inflammation when administered as add-on treatments to the low dose of Methotrexate.
A total of 70 RA patients with active disease will be recruited from Outpatient Clinic of Physical Medicine, Rheumatology and Rehabilitation at Mansoura University hospitals, Mansoura, Egypt will be included in the study. They will be diagnosed with RA according to the American College of Rheumatology/European League Against Rheumatism criteria 2010 (the ACR/EULAR 2010 criteria).
RA Patients who will meet the inclusion criteria will be enrolled in the study.
They will be classified into two groups:
Group 1: 35 RA patients who will receive Methotrexate and placebo for 12 weeks and serve as the control group.
Group 2: 35 RA patients who will receive Methotrexate and Cilostazol 50 mg twice daily for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive Cilostazol 50 mg twice daily with Methotrexate for rheumatoid arthritis for 12 weeks.
Drug: Cilostazol · Drug: Methotrexate
Participants in this arm will receive Placebo with Methotrexate for rheumatoid arthritis for 12 weeks.
Drug: Methotrexate · Drug: Placebo
Cilostazol 50 MG
Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
Placebo
change in DAS-28 CRP score
Clinical assessment by calculating of 28-joint count Disease Activity score (DAS-28) using C-reactive protein according to calculating formula(DAS28 (CRP) = 0.56\*√(Tender joint count28) +0.28\*√(Sowallen joint count28)+0.36\*ln (CRP+1)\*1.10+1.15 will done where high disease activity ≥ 5.1, low disease activity ≤ 3.2, and remission \< 2.6.
Time frame: Baseline,12 weeks
Change in Multi Dimensional Health Assessment score
Functional assessment will be assessed through Multi Dimensional Health Assessment score that include 14 items Health Assessment Questionaire .The score of the HAQ Questionnaire is calculated from the mean of the sum of the responses of the items where each item is scored from 0-3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. in addition, MDHAQ includes the assessment of morning stiffness (MS) duration in minutes.
Time frame: Baseline,12weeks
Change in Visual analog scale for pain
Visual analog scales which ranges from 0 to 10,it is a psychometric scale that is generally used in hospitals and clinics by doctors to conduct pain scale surveys to understand varying degrees of pain or discomfort experienced by a patient.
Time frame: Baseline,12 weeks
Change in the serum level of the assessed biological marker C-reactive protein
C-reactive protein :CRP value (normal range \<1.0 mg/dl). If the value is increased, the disease activity worsened. If the value is reduced the disease activity is improved.
Time frame: Baseline,12weeks
Change in the serum level of the assessed biological marker Nuclear factor kabba-B p65
Transcriptional factor involved intracellular responses to stimuli and stress .So If the value is increased, the disease activity worsened. If the value is reduced the disease activity is improved.
Time frame: Baseline,12weeks
Change in the serum level of the assessed biological marker Hemeoxygenase-1
Hemeoxygenase-1 .
Time frame: Baseline,12weeks
Change in the serum level of the assessed biological marker Cyclic adenosine monophosphate
Cyclic adenosine monophosphate level.
Time frame: Baseline,12weeks
Numbers of participants with treatment-related adverse events
The adverse events in each group will be observed and documented during the whole procedure to show the safety of the treatment.
Time frame: Baseline,12weeks
Started Oct 2022 (actual). Primary completion is estimated for Nov 2024, 25 months after the start.
Of 148 phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 40. This study's planned 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol